Olanzapine/fluoxetine - Eli Lilly and Company
Alternative Names: OFC; Symbyax; ZypZacLatest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Class Antidepressants; Antipsychotics; Benzodiazepines; Propylamines
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bipolar disorders; Major depressive disorder
Most Recent Events
- 15 Apr 2021 Discontinued - Phase-III for Major depressive disorder in Canada, China, South Africa, Turkey, Argentina, Russia, Puerto Rico, India (PO)
- 21 Jun 2012 First Generic equivalent available in USA for Bipolar disorders and Major depressive disorder
- 31 Mar 2012 Eli Lilly completes a phase III trial in Major depressive disorder in Argentina, India, Mexico, Puerto Rico, Russia, South Africa, Turkey and USA (NCT00958568)